Evidence map›Paper›PMID 25633573›Full record

Trial reportJournal of diabetes and its complications2015

Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease.

Tina K Thethi, Muhammad A Bajwa, Husam Ghanim, Chanhee Jo, Monica Weir, Allison B Goldfine, Guillermo Umpierrez, Cyrus Desouza, Paresh Dandona, Ying Fang-Hollingsworth and 2 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of diabetes and its complications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 6 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 6 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Review
  10. Vitamin D: are all compounds equal?Clinical kidney journal · 2025
    Article
  11. Impact of vitamin D and vitamin D receptor activator in diabetic nephropathy.Frontiers in clinical diabetes and healthcare · 2025
    Review
  12. Article
  13. Review
  14. Review
  15. Vitamin D and Diabetic Kidney Disease.International journal of molecular sciences · 2023
    Review
  16. Article
  17. The Role of Vitamin D in Diabetic Nephropathy: A Translational Approach.International journal of molecular sciences · 2022
    Review
  18. Most exposed: the endothelium in chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020
    Review
  19. Vitamin D and cardiovascular disease in chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2019
    Review
  20. The Role of Vitamin D and Oxidative Stress in Chronic Kidney Disease.International journal of environmental research and public health · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Tina K ThethiTulane University Health Sciences Center, New Orleans, LA; Southeast Louisiana Veterans Health Care Systems, New Orleans, LA. Electronic address: tthethi@tulane.edu.
Muhammad A BajwaJoslin Diabetes Center, Boston, MA.
Husam GhanimDiabetes-Endocrinology Center of Western NY, Buffalo, NY.
Chanhee JoScott & White Clinic, Temple, TX.
Monica WeirScott & White Clinic, Temple, TX.
Allison B GoldfineJoslin Diabetes Center, Boston, MA; Harvard Medical School, Boston, MA.
Guillermo UmpierrezEmory University, Atlanta, GA.
Cyrus DesouzaUniversity of Nebraska, Omaha, NB.
Paresh DandonaDiabetes-Endocrinology Center of Western NY, Buffalo, NY.
Ying Fang-HollingsworthScott & White Clinic, Temple, TX.
Vasudevan RaghavanScott & White Clinic, Temple, TX.
Vivian A FonsecaTulane University Health Sciences Center, New Orleans, LA; Southeast Louisiana Veterans Health Care Systems, New Orleans, LA.
Emory University · USHarvard University · USJoslin Diabetes Center · USSoutheast Louisiana Veterans Health Care System · USTulane University · USUniversity of Nebraska at Omaha · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI JUDD E SHELLITO · 2012 to 2026
$69.1M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
X LINKED NYSTAGMUS SYNDROME WITH FEATURES OF ALBINISMM01RR000039 · NCRR · EMORY UNIVERSITY · PI QUYYUMI, ARSHED A · 1985 to 2007
$21.3M
NCATS NIH HHS UL1 TR000454NCRR NIH HHS M01 RR000039NCRR NIH HHS UL1 RR025008NIGMS NIH HHS 1-U54-GM104940NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

aimsPatients with type 2 diabetes (T2DM) and chronic kidney disease (CKD) have impaired endothelial function. Vitamin D and its analogs may play a role in regulation of endothelial function and inflammation. We studied effects of paricalcitol compared to placebo on endothelial function and markers of inflammation and oxidative stress in patients with T2DM and CKD.

methodsA double blind, randomized, placebo-controlled trial was conducted in 60 patients with T2DM and stage 3 or 4 CKD. Paricalcitol 1 mcg or placebo was administered orally once daily for three months. Brachial artery flow mediated dilatation (FMD), nitroglycerine mediated dilation (NMD), and plasma concentrations of inflammatory cytokines, tumor necrosis factor -α and interleukin-6, highly-sensitive C-reactive protein; endothelial surface proteins, intercellular adhesion molecule -1 and monocyte chemo attractant protein-1, and plasma glucose, insulin, free fatty acids, and urinary isoprostane were measured at baseline and end of three months.

results27 patients in the paricalcitol group and 28 patients in the control group completed the study, though analysis of FMD at both time points was possible in 23 patients in each group. There was no significant difference in the change in FMD, NMD or the biomarkers examined after paricalcitol or placebo treatment.

conclusionsTreatment with paricalcitol at this dose and duration did not affect brachial artery FMD or biomarkers of inflammation and oxidative stress. The lack of significance may be due to the fact that the study patients had advanced CKD and that effects of paricalcitol are not additive to the effects of glycemic, lipid and anti-hypertensive therapies.

Indexed as

AdolescentAdultAgedBlood GlucoseC-Reactive ProteinDiabetes Mellitus, Type 2Diabetic NephropathiesDouble-Blind MethodEndothelium, VascularErgocalciferolsFemaleHumansInflammationInsulinMaleMiddle AgedBlood GlucoseC-Reactive ProteinErgocalciferolsInsulinparicalcitolPlacebosChronic kidney diseaseDiabetes mellitusEndothelial dysfunctionInflammationParicalcitol

Identifiers

PMID25633573
PMCPMC4392813
OpenAlexW2150731298

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.